Background. Accumulating evidence suggests that -synuclein aggregates, a defining pathology
Interpretation.
Patients with iRBD displayed similar peripheral dysfunction to symptomatic PD in their sympathetic and parasympathetic nervous systems, and a similar loss of pigmented cells of the LC.
In contrast to PD, 71% of iRBD cases had normal putaminal dopaminergic storage capacity. As iRBD can progress to PD with RBD or DLB, the peripheral dysfunction present in the absence of dopamine terminal damage supports the hypothesis that -synuclein pathology in PD targets peripheral autonomic nerves ahead of involving nigral cells in the midbrain.
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Research in context Background
Prospective studies have shown that most cases of idiopathic rapid-eye-movement sleep behaviour disorder (iRBD) represents a prodromal phenotype of the synucleinopathies Parkinson's disease (PD) or dementia with Lewy bodies (DLB). We searched PubMed in all languages on December 20, 2017 using the keywords "Parkinson disease", "Lewy body disease", "REM sleep behaviour disorder", "positron-emission tomography", "tomography emission-computed singlephoton", "magnetic resonance imaging", "dual-hit hypothesis", "alpha-synuclein". We found no previous in vivo studies which had used multimodal imaging to comprehensively assess the levels of dysfunction in the autonomic nervous system, locus coeruleus, and substantia nigra of patients with iRBD or genetically susceptible prodromal PD cohorts.
Accumulating evidence suggests that the defining pathology of PD, aggregated -synuclein, is capable of cell-to-cell transmission. It has been hypothesised that the initial misfolding and aggregation may occur in the olfactory bulb and autonomic nerve terminals, and then spread centripetally to the brain. This view is supported by evidence that peripheral-to-central spreading of -synuclein can be induced in animal models, by epidemiological evidence that total vagotomy protects against PD, and the finding of pathological -synuclein aggregates in the gut of PD patients years prior to their diagnosis.
Added value of this study
To our knowledge, we present the most comprehensive imaging study to date of iRBD, potentially a prodromal PD+RBD/DLB patient cohort. We demonstrate convincing sympathetic and parasympathetic dysfunction in iRBD patients equivalent to that seen in diagnosed PD patients, along with similar loss of pigmented locus coeruleus cells and thalamic noradrenaline transporters.
In contrast to PD patients, 71% of our iRBD cases had normal 18 F-FDOPA uptake in their putamen.
Introduction
The pathological hallmarks of Parkinson's disease (PD) are progressive loss of nigrostriatal dopaminergic innervation and the presence of abnormal -synuclein (-syn) aggregates in vulnerable neuron populations. Accumulating evidence suggests that misfolded -syn protein can act as a template, encouraging further -syn to misfold with formation of insoluble filamentous inclusions which are capable of cell-to-cell transmission through interconnected neuronal pathways 1 . In most cases of PD, the distribution of brain -syn inclusions displays a characteristic caudo-rostral gradient with the lower brainstem nuclei becoming first involved 2 . It has been hypothesized that -syn aggregates initially form in the olfactory bulb and nerve terminals of the gastrointestinal lining. Subsequently, the pathology spreads via autonomic nerves to the dorsal motor nucleus of the vagus (DMV) and intermediolateral cell columns (IML) of the sympathetic system 3, 4 . This hypothesis is supported by animal studies showing that peripheral-to-central spreading of -syn aggregates through autonomic nerves can be induced 5 , epidemiological evidence that truncal vagotomy is protective against PD 6, 7 , and the finding of -syn inclusions in gastrointestinal nerve fibres many years prior to clinical PD diagnosis 8 . However, human autopsies have failed to support the view that PD is initiated in the gut 9 . Currently, cell-to-cell transmission of aggregated -syn and the peripheral-onset hypothesis are intensely debated topics in PD research 4, 10, 11 .
In the present study, we performed comprehensive multimodal imaging of patients with idiopathic rapid-eye-movement sleep behaviour disorder (iRBD). Most iRBD cases will eventually develop a synucleinopathy -PD with RBD, dementia with Lewy bodies (DLB), or rarely, multiple system atrophy (MSA) 12, 13 . iRBD is believed to arise from degeneration of the pontine nuclei, including the magnocellular reticular formation, sublaterodorsal nucleus, and peri-coeruleus complex 2, 14 . These structures are situated close to the locus coeruleus (LC). Importantly, pathological phosphorylated -syn inclusions have been detected in the colon and sympathetic chain in iRBD patients 15, 16 . If the peripheral-to-central spreading hypothesis of -syn is correct, we predicted that a significant fraction of iRBD cases would display dysfunction of peripheral autonomic nerves equivalent to that seen in symptomatic PD, and that the LC could be involved ahead of the dopamine cells in the substantia nigra compacta which would be relatively spared as iRBD patients do not exhibit overt parkinsonism. We used 11 C-donepezil PET-CT to assess cholinergic (including parasympathetic) activity of the gut 17, 18 , 123 I-MIBG scintigraphy to measure integrity of sympathetic cardiac innervation 19 , neuromelanin-sensitive MRI to measure the density of pigmented cell bodies of the LC 20,21 , 11 C-MeNER PET to assess thalamic noradrenaline transporter binding in the terminals of LC projections 21, 22 , and finally 18 F-DOPA PET to assess nigrostriatal dopamine storage capacity 23 .
Methods

Study design and participants
The study was conducted between 
Imaging
The five imaging modalities and their relationship to neuropathological Braak stages I-III of - All subjects were scanned on either 3T Siemens TRIO or 3T Siemens SKYRA MR systems;
protocols included T1 and fluid-attenuated inversion recovery images. Neuromelanin sensitive images were obtained in a subset of 11 iRBD patients, as previously described 21 . Using a volume of interest (VOI) approach, LC/pons ratios were calculated (Supplementary methods). All MRI and PET analyses were performed in PMOD 3·6 (PMOD, Zürich, Switzerland).
11
C-donepezil PET/CT was performed, as previously described 17 . Subjects fasted for at least 8 hours and abstained from drinking 4 hours before PET. Forty-five minutes after injection of 500 VOIs were defined on the small and large intestine as previously described 17 . Intra-luminal water content was excluded from the small intestine and SUVs were extracted from the VOIs. Small intestine and colon SUVs were adjusted for volume to avoid underestimating the PET signal in PD and iRBD patients 17 .
123 I-MIBG scintigraphy was performed using a dual-head gamma camera (Siemens Symbia SPECT/CT, Erlangen, Germany) with a low-energy high-resolution collimator. PET images were normalized to MNI space with rigid matching of subject's PET to the anatomical MRI, and MRI segmentation using the built-in Hammers N30R83 atlas. For the FDOPA analysis, time-activity curves were extracted from template VOIs placed in the putamen and occipital cortex. The Gjedde-Patlak graphical approach was applied to estimate specific FDOPA uptake (Ki) in putamen using occipital cortex as a reference 28 . The lowest of left/right putamen Ki values was always used for analyses. 11 C-MeNER uptake was investigated in the thalamus and red nucleus, since previous 11 C-MeNER PET studies showed robust PD vs.
healthy control differences in these structures 21, 22 . Template VOIs were defined in the thalamus, red nucleus, and occipital cortex (reference region), as previously described 21 . PET images were smoothed with a 4mm Gaussian filter and time activity curves extracted from VOIs for calculation of binding potentials relative to non-displaceable binding (BPND) using the simplified reference tissue model 2 (SRTM2).
Other assessments
Autonomic and non-motor symptoms were assessed with the non-motor symptoms questionnaire (NMSQuest) 29 , constipation with ROME III diagnostic criteria, motor symptoms with the MDS Unified PD Rating Scale part III (MDS-UPDRS III), and RBD symptoms with the RBD symptom Sticks identification battery.
Statistical analyses
Statistical analyses were performed with Stata 14·2 and Graphpad PRISM 6. Normality of data was assessed with Shapiro-Wilk tests and Q-Q plots. Data are presented as mean±SD or median (range). Grubbs' test was used to identify statistical outliers. Demographic and clinical data were interrogated using ANOVA, Kruskal-Wallis, and chi-squared tests as appropriate. Group comparisons of imaging data were performed with one-way ANOVA. The iRBD group was subsequently compared to the control and PD groups applying Dunnett's correction for multiple comparisons. Associations between imaging data and clinical data were investigated with Pearson correlation or Spearman Rank correlation for continuous and categorical data. Significance level was set at p <0·05.
Pathology index
To assess the degree to which iRBD subjects had reached "fully developed PD-level pathology"
within each neuronal system, we converted the iRBD imaging data to a "PD pathology index", by defining the corresponding healthy control mean as 0% and the PD mean as 100%. Resulting pathology indices were compared to published data from previous 123 I-MIBG studies 19, 31 and 123 I-FP-CIT dopamine transporter studies of iRBD patients 32, 33 , where controls and PD patient comparator data were presented.
Role of the funding source
The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Clinical and demographic data
The iRBD group was 6 years older than the PD comparator group for 11 C-donepezil PET (p=0·04), and the male/female ratio across the three 123 I-MIBG subject groups was unmatched (p=0·059). There were no other significant differences in age or sex-distribution between the iRBD and comparator PD and control groups. Self-reported duration of RBD symptoms in the iRBD group was 6·3±5·6 years. The iRBD patients showed similar rates of hyposmia, orthostatic hypotension, and non-motor symptoms compared to all PD reference groups. Twenty of 22 (91%) iRBD patients were hyposmic. Two iRBD cases had MoCA scores of 23 and 24, while the remaining 20 subjects fell in the 25-30 range. These data are summarized in Table 1 .
Imaging data
Images from the five modalities are presented in Figure 2 . Due to logistical challenges and technical failures, there were a few missing scans in the study. All 22 iRBD patients underwent MIBG scintigraphy, 21 had FDOPA PET, 20 donepezil PET, and 17 MeNER PET. Only 11 iRBD patients had neuromelanin-sensitive MRI. See Table 1 for exact numbers of subjects within each imaging modality. The median time lag from the first to last imaging session in the iRBD cohort was 92 days (range 7-265).
11 C-donepezil PET. Significant between-group differences in 11 C-donepezil uptake were seen in the small intestine (p=0·004, ANOVA, Figure 3A) , and the colon (p=0·004, ANOVA, Figure 3B ).
Compared to healthy controls, iRBD patients displayed significantly lower uptake in the small intestine (p=0·0018) and colon (p=0·0020). Mean small intestine and colon values in the iRBD group were similar to PD patients (small intestine p=0·348, colon p=0·388). There was no significant correlation between colon 11 C-donepezil SUV and severity of constipation ROME (questions 9-15) ratings (p=0·42). 
B.
123 I-MIBG scintigraphy of the heart (arrow). Note completely absent heart uptake in iRBD and PD. C. Neuromelanin (NM) MRI of locus coeruleus (arrows). Note lower locus coeruleus signal in iRBD and PD. D.
11 CMeNER PET. Thalamic MeNER binding potential (BPND), shown by arrows, is decreased in iRBD and PD. E. 18 F-DOPA PET. Putamen FDOPA signal (arrows) is mildly decreased in some iRBD cases, but markedly decreased in PD.
123 I-MIBG scintigraphy. Highly significant between-group differences were seen in the late-image mean H/M ratios (p<0·0001, ANOVA, Figure 3C ) and also in the MIBG WR (p<0·0001, ANOVA, Figure 3D ). Compared to controls, the iRBD group showed significantly lower H/M ratios (p<0·0001) and WR (p<0·0001). No mean difference was seen between the iRBD and PD groups (p>0·21). Using a cut-off criterion of ">2 SD below control mean" to define a pathological MIBG scan, 18 of 22 (82%) iRBD patients had pathological H/M ratios, and 20 of 22 (91%) iRBD had pathological WR rates. No significant correlations were seen between systolic or diastolic blood pressure drop and the H/M ratios or WR values (p>0·25). Neuromelanin MRI. Highly significant differences were seen between the groups in neuromelanin LC/pons ratios (p=0·0004, ANOVA, Figure 4A ). iRBD patients displayed significantly lower LC/pons ratios compared to the controls (p=0·0028) but similar to those of PD patients (p=0·96). Figure 1) . The 11 C-MeNER BPND of the red nucleus also differed significantly across the three groups with reductions evident in iRBD and PD (p=0·033, ANOVA, Figure 4C ), but no significant differences were seen when comparing the iRBD group with the healthy controls (p=0·103) or PD patients (p=0·74).
F-DOPA PET.
Highly significant between-group differences were seen in putamen FDOPA Ki values (p<0·0001, ANOVA; Figure 4D ). When using a ">2 SD below control mean" criterion of pathology, 6 of 21 (29%) iRBD patients had pathologically reduced putamen FDOPA uptake. In contrast, all PD patients had pathological FDOPA PET, and a highly significant difference was seen in mean FDOPA Ki values between iRBD and PD groups (p<0.0001).
Supplementary Figure 1 . The 11 C-MeNER PET binding potential (BPND) in the left (A) and right (B) thalamus of healthy controls (HC), iRBD, and PD patients. An overall difference in thalamic 11 C-MeNER BPND was seen between the groups in the left thalamus (p=0·004, A), and post-ANOVA comparison of the iRBD to control group showed that the 11 C-MeNER BPND reduction was significant in the left thalamus (p=0·023). Dotted lines denote -1 and -2 SD below control mean. 
Pathology index
Discussion
The "peripheral-onset" of PD hypothesis posits that formation of abnormal -syn aggregates first occurs in nerve terminals of the olfactory, enteric, and autonomic nervous system. The aggregates then spread by retrograde axonal transport to the medullary DMV and spinal IML 3 .
Here, we have demonstrated peripheral dysfunction at a level seen in established PD level in our iRBD patients who are likely to represent prodromal PD or DLB. Our findings do not prove that -syn misfolding is initiated peripherally by neurotropic pathogens, but are compatible with this view. Our findings argue against an isolated olfactory entry site of pathogens in PD 11, 34 as this would be difficult to reconcile with our observed cardiac and intestinal dysfunction and concomitant sparing of the nigra in iRBD. Nearly all our iRBD patients had pathological MIBG heart scans, in accordance with two previous, smaller iRBD studies 19, 31 . Taken together, the available data show that approximately 90% of iRBD patients have profound cardiac sympathetic denervation. We saw no correlations between MIBG signals and severity of orthostatic hypotension in iRBD; this is also the case in PD 35 . Interestingly, 40-50% of H&Y stage I PD patients have normal MIBG scans, but by stage H&Y III nearly all have pathological MIBG 31 . In the light of our MIBG results in iRBD, it is possible that those early-stage PD patients with normal MIBG scans are predominantly RBDnegative 36, 37 . We propose that the prodromal RBD phenotype of PD is characterized by early, severe pathology in the autonomic nervous system whereas RBD-negative early PD patients are less susceptible. This interpretation is supported by a previous MIBG report, which compared iRBD to PD patients across H&Y stages I through V 31 . These authors found MIBG pathology indices in iRBD of 300% (compared to H&Y I PD), 127% (H&Y II), 110% (H&Y III), and 102%
(H&Y IV) (grey inserts in Figure 5 ).
The iRBD group displayed a similar reduction in LC neuromelanin signal to our diagnosed PD patients. The PD comparator group comprised 15 polysomnography-verified RBD-positive and 14 RBD-negative patients 21 . Our iRBD patients displayed a larger mean reduction in LC neuromelanin signal than the RBD-negative PD sub-group, although the difference was non-significant (Supplementary Figure 2) 21 . These observations are in line with previous studies of iRBD and PD 20, 38 and reinforce the conclusion that iRBD patients exhibit a more profound loss of LC neuromelanin than diagnosed PD patients without RBD. Damage to pontine nuclei, including sublaterodorsal nucleus and peri-coeruleus complex, is thought to be responsible for generating the RBD phenotype 14 .
Supplementary Figure 2 . The MRI neuromelanin LC/pons ratio in healthy controls (HC), iRBD, and PD patients with and without RBD. No significant differences were seen between iRBD and either PD group (iRBD vs. PD-RBD: p=0·344, iRBD vs. PD+RBD: p=0·662). However, the iRBD group displayed significantly lower values than the HC group (p=0·004). [Dotted line denotes 1 SD below control mean]. 
LC/pons ratio
MeNER gives a low specific signal, so our study may well have lacked the power to detect bilaterally significant thalamic 11 C-MeNER reductions with this intrinsically noisy tracer.
29% of our iRBD patients exhibited decreased putaminal FDOPA uptake in line with previous dopamine transporter imaging studies 39, 40 . Our PD comparator group for FDOPA had established disability ( Table 1 ) so severe nigrostriatal dopaminergic deficits would be expected ( Figure 4D ).
The use of this PD group as a comparator resulted in a low FDOPA pathology index for the iRBD patients (21%) which could have been higher if iRBD had been compared with newly diagnosed PD cases. FDOPA PET is a marker of aromatic L-amino acid decarboxylase and this becomes upregulated in remaining terminals during the early stages of nigrostriatal degeneration 41 . Such upregulation could mask early dopaminergic dysfunction in iRBD when FDOPA PET is used as an imaging biomarker. Nevertheless, normal presynaptic dopamine imaging is considered an exclusion criterion for a PD diagnosis 24 . Since 71% of our iRBD subjects had normal putamen FDOPA uptake, we conclude that the dopaminergic system is considerably less affected in iRBD compared to the dusfunction of the autonomic nervous system and the LC.
We emphasize that our iRBD findings may only represent a valid prodrome of PD patients with additional RBD. It is accepted that RBD is associated with a more aggressive PD phenotype which shows more widespread -syn deposition affecting most brain regions 42 , and faster progression of motor and non-motor symptoms 43 . We have demonstrated that the level of dysfunction in the autonomic nervous system of iRBD patients equals, and at times exceeds, that seen in unselected PD patients. Based on its pattern of autonomic and LC involvement, we hypothesize that noncognitively impaired iRBD parallels the Braak stage 2 PD distribution of Lewy pathology 2 . We speculate that this supports the view that, during the prodromal phase of PD or DLB with RBD, the -syn pathology responsible originates in peripheral autonomic/enteric nerve terminals. In contrast, RBD-negative early-stage PD patients may have a more benign phenotype where -syn pathology is primarily initiated within the CNS and olfactory bulb. This hypothesis is speculative, but would explain why not all PD patients show a Braak-like distribution of -syn pathology at post-mortem -20% of cases have no pathology in the DMV 11 .
The dual-hit hypothesis is based on post-mortem Braak staging of PD brains 2 , however, DLB cases can exhibit alternative distributions of -syn pathology 44 . Our choice to study iRBD as a prodrome of PD can be criticized as ~50% of iRBD subjects will convert to DLB 12, 13 . Despite this caveat, our findings strongly suggest that iRBD represents a prodrome of both DLB and PD with RBD and these patients are similar with respect to having early peripheral autonomic and LC dysfunction. We will follow-up our iRBD cases to determine whether those patients with a final PD+RBD diagnosis show more extensive peripheral dysfunction than the DLB converters. Finally,
we propose that MIBG scintigraphy may be useful for predicting which iRBD cases will progress to clinical MSA as cardiac sympathetic innervation is preserved in this synucleinopathy 35 . We speculate that those iRBD cases with normal MIBG scans have a higher probability of representing prodromal MSA. This assertion needs confirmation in future studies.
The pattern of neuronal cell loss seen in PD does not parallel the severity of Lewy pathology and it has been suggested that regional or cell-related factors could be responsible for this 9, 11 . Our findings are relevant to this discussion, since we primarily used markers of nerve terminal function, not cell body loss. -syn is a synaptic protein and its initial aggregation is thought to take place in neuronal terminals 1 . Studies have shown a more dramatic loss of nerve terminals compared to cell bodies across several neurotransmitter systems in PD 35, 45 . This implies that neurons containing Lewy pathology will be most dysfunctional at a synaptic level, while their cell bodies may remain intact. Our results in iRBD show a pattern of neuronal terminal damage that parallels Braak stage 2 of Lewy body pathology although cell body loss measured in post-mortem studies of early PD patients does not follow Braak -syn staging. The fact that some neurons containing -syn aggregates are more resistant to apoptosis than others is not against the hypothesis that -syn aggregates can be transmitted through inter-connected neuronal networks, nor that the initial -syn aggregation may first occur in peripheral nerve terminals in some individuals.
This study has several limitations: First, we used different groups of healthy controls and PD patients as comparators when analysing iRBD imaging findings. This was to limit levels of radiation exposure to healthy and PD subjects and maintain scan tolerance as far as possible in our complex PET/MRI programme. However, except for minor differences in age distribution of the C-MeNER analyses. These cases, however, are not easy to find and recruit for complex imaging programmes. Fourth, since 11 C-donepezil PET is not a specific parasympathetic marker, the significant intestinal 11 C-donepezil signal reductions in iRBD may indicate both parasympathetic and local enteric nerve terminal damage.
In conclusion, iRBD patients display neuronal dysfunction in the peripheral autonomic nervous system and locus coeruleus equivalent to diagnosed PD patients although 71% of these iRBD patients have normal nigrostrial dopaminergic innervation. This pattern of dysfunction parallels
Braak stage 2 -syn pathology in PD and supports the hypothesis that -syn misfolding and aggregation in iRBD, a prodrome of both PD and DLB with RBD, initially targets terminals of the peripheral nervous system. neuromelanin MRI]
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